论文部分内容阅读
骨质疏松症是肾移植患者常见的并发症之一,严重影响到移植肾受者的生活质量,造成移植肾受者骨量减低的原因是多方面的,其中重要的原因之一就是激素的长期应用。由于肾移植患者须合用糖皮质激素及其他免疫抑制剂以控制症状,但其最佳剂量既可最大地控制患者病情,又可尽可能小地减少对肾移植受者骨量产生影响仍有待进一步地研究与统一。为了尽可能地改善移植肾受者的骨量以提高其生存质量,有多项研究资料表明,维生素D与膦酸盐类药物可能会改善肾移植受者的骨密度。
Osteoporosis is one of the common complication of renal transplantation patients, seriously affecting the quality of life of renal transplant recipients, resulting in renal transplant recipients have many reasons for bone loss, one of the important reasons is the hormone Long-term application. Because kidney transplant patients must be combined with glucocorticoids and other immunosuppressive agents to control symptoms, but its best dose can both control the patient’s condition, but also minimize the impact on bone mass in renal transplant recipients remains to be further Study and unify. In order to improve bone mass in renal transplant recipients as much as possible to improve their quality of life, a number of studies have shown that vitamin D and phosphonates may improve bone mineral density in kidney transplant recipients.